MUFG Americas Holdings Corp decreased its holdings in Becton, Dickinson and Company (NYSE:BDX) by 4.2% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 17,971 shares of the medical instruments supplier’s stock after selling 793 shares during the quarter. MUFG Americas Holdings Corp’s holdings in Becton, Dickinson and were worth $3,506,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also made changes to their positions in BDX. Almanack Investment Partners LLC. purchased a new stake in Becton, Dickinson and in the first quarter worth $105,000. Parkside Financial Bank & Trust lifted its stake in Becton, Dickinson and by 1.4% in the first quarter. Parkside Financial Bank & Trust now owns 633 shares of the medical instruments supplier’s stock worth $116,000 after acquiring an additional 9 shares during the period. QCI Asset Management Inc. NY lifted its stake in Becton, Dickinson and by 9.2% in the first quarter. QCI Asset Management Inc. NY now owns 710 shares of the medical instruments supplier’s stock worth $130,000 after acquiring an additional 60 shares during the period. Financial Architects Inc lifted its stake in Becton, Dickinson and by 8.0% in the second quarter. Financial Architects Inc now owns 731 shares of the medical instruments supplier’s stock worth $142,000 after acquiring an additional 54 shares during the period. Finally, Guardian Life Insurance Co. of America lifted its stake in Becton, Dickinson and by 0.7% in the first quarter. Guardian Life Insurance Co. of America now owns 819 shares of the medical instruments supplier’s stock worth $150,000 after acquiring an additional 6 shares during the period. 87.12% of the stock is owned by institutional investors.

In related news, insider Gary M. Cohen sold 15,512 shares of the company’s stock in a transaction on Monday, September 11th. The stock was sold at an average price of $203.77, for a total transaction of $3,160,880.24. Following the completion of the sale, the insider now directly owns 95,781 shares in the company, valued at approximately $19,517,294.37. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Linda M. Tharby sold 4,695 shares of the company’s stock in a transaction on Tuesday, August 22nd. The stock was sold at an average price of $200.48, for a total value of $941,253.60. Following the sale, the executive vice president now owns 18,670 shares of the company’s stock, valued at $3,742,961.60. The disclosure for this sale can be found here. Insiders have sold a total of 75,904 shares of company stock valued at $15,242,688 over the last 90 days. 1.40% of the stock is currently owned by company insiders.

COPYRIGHT VIOLATION NOTICE: “Becton, Dickinson and Company (BDX) Shares Sold by MUFG Americas Holdings Corp” was first published by Watch List News and is the property of of Watch List News. If you are viewing this piece on another domain, it was stolen and reposted in violation of United States & international copyright and trademark legislation. The original version of this piece can be accessed at https://www.watchlistnews.com/becton-dickinson-and-company-bdx-shares-sold-by-mufg-americas-holdings-corp/1579412.html.

Several brokerages have commented on BDX. Zacks Investment Research raised Becton, Dickinson and from a “hold” rating to a “buy” rating and set a $225.00 price objective for the company in a research report on Monday, July 17th. Raymond James Financial, Inc. raised Becton, Dickinson and from an “outperform” rating to a “strong-buy” rating and lowered their price objective for the company from $210.00 to $180.00 in a research report on Friday, June 30th. BidaskClub raised Becton, Dickinson and from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, July 11th. Cowen and Company reissued a “buy” rating and set a $230.00 price objective on shares of Becton, Dickinson and in a research report on Monday, August 14th. Finally, Bank of America Corporation reissued a “buy” rating and set a $225.00 price objective (up previously from $200.00) on shares of Becton, Dickinson and in a research report on Friday, July 21st. One investment analyst has rated the stock with a sell rating, five have given a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Becton, Dickinson and currently has an average rating of “Buy” and an average price target of $196.93.

Becton, Dickinson and Company (NYSE BDX) opened at 191.56 on Friday. The company has a market capitalization of $43.59 billion, a P/E ratio of 55.48 and a beta of 1.06. The stock’s 50 day moving average price is $199.01 and its 200 day moving average price is $191.58. Becton, Dickinson and Company has a one year low of $161.29 and a one year high of $206.63.

Becton, Dickinson and (NYSE:BDX) last issued its quarterly earnings data on Thursday, August 3rd. The medical instruments supplier reported $2.46 earnings per share for the quarter, topping analysts’ consensus estimates of $2.44 by $0.02. The firm had revenue of $3.04 billion during the quarter, compared to analysts’ expectations of $3.06 billion. Becton, Dickinson and had a return on equity of 22.53% and a net margin of 6.25%. The firm’s quarterly revenue was down 5.1% on a year-over-year basis. During the same period in the prior year, the business posted $2.35 EPS. Equities analysts anticipate that Becton, Dickinson and Company will post $9.46 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, September 29th. Investors of record on Friday, September 8th will be paid a dividend of $0.73 per share. This represents a $2.92 dividend on an annualized basis and a dividend yield of 1.52%. The ex-dividend date of this dividend is Thursday, September 7th. Becton, Dickinson and’s dividend payout ratio (DPR) is currently 83.43%.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with Analyst Ratings Network's FREE daily email newsletter.